BEMPEDOIC ACID (NEXLETOL®)

















  • Values are average percent change from baseline
  • 95% of patients had established ASCVD and 5% had HeFH
  • Average baseline LDL level was 103 mg/dl
  • Reference [1]
Effects of Bempedoic Acid on Lipid Parameters in Patients with HeFH and/or ASCVD on Maximally Tolerated Statin Therapy at 12 weeks
Bempedoic acid 180 mg
(N=1488)
Placebo
(N=742)
Total -10% +1%
LDL -17% +2%
Non-HDL cholesterol -12% +2%
apo B -9% +3%





  • Reference [1]
Side effect Bempedoic acid + statin
(N=2009)
Placebo + statin
(N=999)
Upper respiratory tract infection 4.5% 4.0%
Muscle spasms 3.6% 2.3%
Hyperuricemia 3.5% 1.1%
Back pain 3.3% 2.2%
Abdominal pain or discomfort 3.1% 2.2%
Bronchitis 3.0% 2.5%
Pain in extremity 3.0% 1.7%
Anemia 2.8% 1.9%
Elevated liver enzymes 2.1% 0.8%
Atrial fibrillation 1.7% 1.1%
New-onset BPH in men 1.3% 0.1%

















Bempedoic acid (Nexletol®)

Dosage forms

Tablet
  • 180 mg

Dosing

High cholesterol
  • 180 mg once daily
  • May take without regard to food
  • Check lipids 8 - 12 weeks after starting
  • Bempedoic acid should be taken with with maximally tolerated statin therapy

Generic / Price

- NO/$$$$

Bempedoic acid + Ezetimibe (Nexlizet®)

Dosage forms

Tablet
  • Bempedoic acid - Ezetimibe
    • 180 mg - 10 mg

Dosing

High cholesterol
  • 180/10 mg once daily
  • May take without regard to food
  • Swallow tablet whole
  • Check lipids 8 - 12 weeks after starting
  • Nexlizet should be taken with with maximally tolerated statin therapy

Generic / Price

- NO/$$$$